Trazimera

Država: Europska Unija

Jezik: engleski

Izvor: EMA (European Medicines Agency)

Aktivni sastojci:

trastuzumab

Dostupno od:

Pfizer Europe MA EEIG

ATC koda:

L01FD01

INN (International ime):

trastuzumab

Terapijska grupa:

Antineoplastic agents

Područje terapije:

Stomach Neoplasms; Breast Neoplasms

Terapijske indikacije:

Breast cancerMetastatic breast cancerTrazimera is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer: (MBC):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatments.in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable.in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.Early breast cancerTrazimera is indicated for the treatment of adult patients with HER2 positive early breast cancer. (EBC).following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel.in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.in combination with neoadjuvant chemotherapy followed by adjuvant Trazimera therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.Trazimera should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.Metastatic gastric cancerTrazimera in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.Trazimera should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result. Accurate and validated assay methods should be used.

Proizvod sažetak:

Revision: 11

Status autorizacije:

Authorised

Datum autorizacije:

2018-07-26

Uputa o lijeku

43
B. PACKAGE LEAFLET
44
PACKAGE LEAFLET: INFORMATION FOR THE USER
TRAZIMERA 150 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
TRAZIMERA 420 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
trastuzumab
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Trazimera is and what it is used for
2.
What you need to know before you are given Trazimera
3.
How Trazimera is given
4.
Possible side effects
5.
How to store Trazimera
6.
Contents of the pack and other information
1.
WHAT TRAZIMERA IS AND WHAT IT IS USED FOR
Trazimera contains the active substance trastuzumab, which is a
monoclonal antibody. Monoclonal
antibodies attach to specific proteins or antigens. Trastuzumab is
designed to bind selectively to an
antigen called human epidermal growth factor receptor 2 (HER2). HER2
is found in large amounts
on
the surface of some cancer cells where it stimulates their growth.
When Trazimera binds to HER2
it
stops the growth of such cells and causes them to die.
Your doctor may prescribe Trazimera for the treatment of breast and
gastric cancer when:
•
You have early breast cancer, with high levels of a protein called
HER2.
•
You have metastatic breast cancer (breast cancer that has spread
beyond the original tumour)
with high levels of HER2. Trazimera may be prescribed in combination
with the
chemotherapy
medicine paclitaxel or docetaxel as first treatment for metastatic
breast cancer
or it may be
prescribed alone if other treatments have proved unsuccessful. It is
also used in
combination
with medicines called aromatase inhibitors with patients with high
levels of
HER2 and hormone
receptor-positive metastatic breast cancer (cancer that is

Svojstava lijeka

1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Trazimera 150 mg powder for concentrate for solution for infusion
Trazimera 420 mg powder for concentrate for solution for infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Trazimera 150 mg powder for concentrate for solution for infusion
One vial contains 150 mg of trastuzumab, a humanised IgG1 monoclonal
antibody produced by
mammalian (Chinese hamster ovary) cell suspension culture and purified
by chromatography
including specific viral inactivation and removal procedures.
Trazimera 420 mg powder for concentrate for solution for infusion
One vial contains 420 mg of trastuzumab, a humanised IgG1 monoclonal
antibody produced by
mammalian (Chinese hamster ovary) cell suspension culture and purified
by chromatography
including specific viral inactivation and removal procedures.
The reconstituted Trazimera solution contains 21 mg/mL of trastuzumab.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder for concentrate for solution for infusion (powder for
concentrate).
White lyophilised powder or cake.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Breast cancer
_Metastatic breast cancer_
Trazimera is indicated for the treatment of adult patients with
HER2-positive metastatic breast
cancer (MBC):
-
as monotherapy for the treatment of those patients who have received
at least two
chemotherapy
regimens for their metastatic disease. Prior chemotherapy must have
included at
least an
anthracycline and a taxane unless patients are unsuitable for these
treatments.
Hormone receptor
positive patients must also have failed hormonal therapy, unless
patients are
unsuitable for these
treatments.
-
in combination with paclitaxel for the treatment of those patients who
have not received
chemotherapy for their metastatic disease and for whom an
anthracycline is not suitable.
-
in combination with docetaxel for the treatment of those patients who
have not received
chemotherapy for their metastatic disease.
3
-
in combinat